**Core Concept**
Triple therapy in Rheumatoid Arthritis (RA) typically involves a combination of a disease-modifying antirheumatic drug (DMARD), a biologic agent, and a corticosteroid to achieve optimal control of symptoms and prevent disease progression.

**Why the Correct Answer is Right**
The combination of a DMARD (e.g., methotrexate) and a biologic agent (e.g., tumor necrosis factor-alpha inhibitor) is a cornerstone of triple therapy in RA. Corticosteroids, such as prednisone, are often used as bridging therapy to quickly control inflammation and prevent joint damage while the DMARD and biologic agent take effect. The corticosteroid dose is gradually tapered as the DMARD and biologic agent become effective.

**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect because it is not a component of triple therapy in RA. However, it is a common treatment for osteoporosis and can be used in patients with RA who are at high risk of osteoporosis.
**Option B:** This option is incorrect because it is a type of biologic agent used in the treatment of RA, but it is not a component of triple therapy. It is often used in combination with a DMARD and corticosteroid.
**Option C:** This option is incorrect because it is a type of DMARD, but it is not a component of triple therapy in RA. It is often used as monotherapy in patients with mild RA.

**Clinical Pearl / High-Yield Fact**
In patients with RA, the combination of a DMARD and biologic agent has been shown to improve disease outcomes and reduce the risk of radiographic progression compared to monotherapy or corticosteroid therapy alone.

**Correct Answer:** A.